OncView™ Podcast: Immunotherapy Response Monitoring in Lung Cancer


In an OncView program, Roy Herbst, MD, PhD, touched on clinical decision-making, monitoring response, and the potential treatment options available for treating non–small cell lung cancer.

As part of its OncView video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies for selecting immunotherapy in the treatment of non–small cell lung cancer (NSCLC).

In the video series, Herbst discussed the following:

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
Related Content